Roche, the Swiss pharmaceutical giant, has announced a $50 billion investment aimed at bolstering its manufacturing operations in the United States over the next five years. This substantial investment is projected to create more than 12,000 jobs, including significant construction roles. Roche's expansion includes new factories in Pennsylvania and Indiana, as well as research facilities in Massachusetts, with the goal of increasing exports from the US. The move is partly in response to the looming threat of sector-specific tariffs under the Trump administration, demonstrating a proactive strategy to ensure growth and innovation in the pharmaceutical sector.
Roche's $50 billion investment in US manufacturing aims to create over 12,000 jobs and counter potential tariffs, marking a significant commitment to innovation and growth.
The investment includes 6,500 construction jobs and will expand existing facilities which, once operational, will result in more exports than imports from the US.
Roche plans to build new factories for gene therapy and glucose monitoring, alongside a research center for cardiovascular and metabolic studies, enhancing healthcare innovation.
Thomas Schinecker stated that this foundational investment will benefit patients globally, emphasizing a strategic response to potential tariff challenges and the need for growth.
Collection
[
|
...
]